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Vandetanib (ZactimaTM) is a novel,  orally available inhibitor of both vascular endothelial growth fac-
tor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase.  In the pres-
ent study,  a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to 
a human EGFR mutation (delE746-A750) was established.  The transgenic mice developed atypical 
adenomatous hyperplasia to adenocarcinoma of the lung at around 5 weeks of age and died of lung 
tumors at approximately 17 weeks of age.  In the mice treated with vandetanib (6mg/kg/day),  these 
lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues 
to levels comparable to those of non-transgenic control mice.  The median overall survival time of the 
transgenic mice was 28 weeks in the vandetanib-treated group and 17 weeks in the vehicle-treated 
group.  Vandetanib signiﬁcantly prolonged the survival of the transgenic mice (log-rank test,  p＜
0.01); resistance to vandetanib occurred at 20 weeks of age and the animals died from their lung 
tumors at about 28 weeks of age.  These data suggest that vandetanib could suppress the progression 
of tumors harboring an activating EGFR mutation.
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F or the year 2012,  the WHO reported 1.59 mil-lion deaths from lung cancer [http://www.who.
int/mediacentre/factsheets/fs297/en/ (accessed Dec 
1,  2015)],  making it the most common cause of cancer 
death globally.  Despite progress in the treatment of 
lung cancer by surgical resection,  radiotherapy,  and 
chemotherapy,  the prognosis of patients with advanced 
disease remains poor.  Indeed,  the 5-year survival rate 
for patients with advanced non-small-cell lung cancer 
(NSCLC) is around 15  [1].
　 The growth and maintenance of tumors such as 
NSCLC is dependent upon cellular as well as extra-
cellular processes.  Epidermal growth factor receptor 
(EGFR) signaling regulates many of the cellular pro-
cesses essential for tumor initiation and progression,  
including motility,  adhesion,  tumor invasion,  cell 
survival,  angiogenesis,  and proliferation [2].  The 
importance of EGFR in cancer has been therapeuti-
cally exploited by the use of agents such as EGFR 
tyrosine kinase inhibitor (TKI) and EGFR monoclonal 
antibodies,  both of which have been proven to be of 
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clinical beneﬁt in the treatment of advanced NSCLC 
[3,  4].
　 The expansion,  invasion,  and metastasis of malig-
nant tumors are processes that depend upon an ade-
quate supply of nutrients and oxygen from functional 
blood vessels.  Vascular endothelial growth factor 
(VEGF) and vascular endothelial growth factor recep-
tor (VEGFR) play important roles in the formation of 
new blood vessels (angiogenesis) [5].  VEGFR signal-
ing regulates vascular permeability and is crucial to 
vasculogenesis,  angiogenesis,  and endothelial integrity 
and survival [6,  7].  In most types of cancers,  includ-
ing NSCLC,  breast cancers,  prostate cancer,  and 
colorectal cancers,  VEGF is overexpressed and is 
generally associated with increases in microvascular 
density [7,  8].  VEGF and VEGFR are therefore 
attractive targets for anticancer therapy.  Several 
studies have shown an improvement in the outcomes of 
patients with metastatic NSCLC,  colorectal cancer,  
and breast cancer who were treated with a combina-
tion of bevacizumab,  an anti-VEGF antibody,  and 
chemotherapy [9-13].  Moreover,  several approaches 
to the blocking of VEGF activity are under develop-
ment,  including anti-VEGF antibodies,  anti-VEGFR 
antibodies,  VEGF trapping,  and VEGFR TKI [8].
　 Lung cancer development and progression likely 
involve the dysregulation of both EGFR and VEGFR 
signaling.  Accordingly,  the inhibition of these two 
receptor-signaling pathways is an attractive strategy 
to treat advanced NSCLC [11-13].  Vandetanib is an 
orally available inhibitor of VEGFR-2,  EGFR,  and 
RET tyrosine kinase activity [14].  A randomized,  
double-blind Phase III study (ZEPHYR) did not dem-
onstrate an overall survival beneﬁt for vandetanib 
versus placebo,  but vandetanib did show statistically 
signiﬁcant advantages versus placebo in terms of the 
progression-free survival and objective response rate 
[15].  Subsequently,  5 randomized clinical trials were 
performed to compare chemotherapy with or without 
vandetanib in patients with advanced NSCLC.  The 
results showed a signiﬁcantly longer progression-free 
survival by chemotherapy with vandetanib but did not 
show any advantage of this therapy for overall sur-
vival (OS) [16-19].
　 In the present study,  a line of transgenic mice 
harboring the mouse Egfr mutation (delE748-A752) 
under the control of a type-II-pneumocyte-speciﬁc 
surfactant protein C (SPC) promoter [18] was estab-
lished.  These transgenic mice developed a spectrum of 
pathological changes in their lungs,  ranging from 
atypical adenomatous hyperplasia to invasive adeno-
carcinoma,  and died due to multifocal invasive adeno-
carcinoma at around 17 weeks of age.  This mouse 
model of lung cancer resembles the clinical course of 
human adenocarcinomas harboring an activating EGFR 
mutation and thus enables evaluation of the direct and 
indirect eﬀects of tyrosine kinase inhibition on tumor 
cells and neovascular vessels,  respectively,  under 
physiologically and pathologically relevant conditions.
　 The speciﬁc aims of this study were to evaluate the 
eﬃcacy of vandetanib in the mutated Egfr transgenic 
mouse model and to elucidate the mechanisms of 
acquired resistance to vandetanib.
Materials and Methods
　 Transgenic mice. Transgenic mice were estab-
lished as reported previously [20].  These mice harbor 
the mouse Egfr mutation del E748-A752,  which cor-
responds to the major activating human EGFR muta-
tion (del E746-A750),  under the control of a type-II-
pneumocyte-speciﬁc SP-C promoter (kindly provided 
by Dr. Jeﬀrey A. Whitsett,  the Division of Neonatology 
Perinatal and Pulmonary Biology at Cincinnati 
Childrenʼs Hospital Medical Center,  OH,  USA).  
Pathological changes ranging from atypical adenocar-
cinoma to invasive adenocarcinoma of the lung devel-
oped in the transgenic mice beginning at around 5 
weeks of age,  and the animals died from multifocal 
adenocarcinoma of the lung at about 17 weeks of age.
　 Animal husbandry. All animals were kept 
under pathogen-free conditions with abundant food and 
water,  as speciﬁed in the guidelines of the Department 
of Animal Resources,  Okayama University Advanced 
Science Research Center.  Vandetanib (6mg/kg;  
AstraZeneca,  Macclesﬁeld,  UK) was given as an oral 
suspension once a day by gavage.  The vandetanib 
suspension was obtained by homogenization in 1  
polysorbate 80 followed by ball-milling with glass 
beads for 24 h.
　 Histology, immunohistochemistry, and immu-
nofluorescence. The animals were killed by cer-
vical dislocation and their lungs excised.  The left lung 
was ﬂash-frozen in liquid nitrogen for molecular analy-
sis,  and the right lung was inﬂated with 10  parafor-
maldehyde in phosphate-buﬀered saline (PBS).  The 
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lungs were subsequently ﬁxed in 10  paraformalde-
hyde overnight at room temperature,  embedded in 
paraﬃn,  and sectioned in 5-µm slices (West Japan 
Pathology,  Okayama,  Japan).  Heat-induced antigen 
retrieval was performed by treatment with a PASCAL 
pressure cooker (Dako,  Glostrup,  Denmark) accord-
ing to the manufacturerʼs protocol.  Endogenous per-
oxidase activity was quenched with 3  hydrogen per-
oxide in methanol for 10min.  After incubation with 
blocking solution for 60min,  the sections were incu-
bated with primary antibody (1 : 50 dilution) at 4℃ for 
12 h,  followed by a 20-min incubation with a labeled 
polymer horseradish peroxidase (HRP) anti-rabbit 
antibody (EnVision＋System; Dako).  The sections 
were then stained with diaminobenzidine chromogen 
and counterstained with Mayerʼs hematoxylin.  The 
primary antibodies used were rabbit polyclonal anti-
EGFR anti-phospho-VEGFR2 (Santa Cruz 
Biotechnology,  Santa Cruz,  CA,  USA),  anti-phos-
pho-EGFR (Cell Signaling Technology,  Danvers,  
MA,  USA),  and VEGFR2 (Biosource International,  
Camarillo,  CA,  USA).  The eﬀect of vandetanib on 
apoptosis and microvessel density was evaluated by 
immunoﬂuorescence microscopy of frozen lung tissue 
from vandetanib-treated and vehicle-treated transgenic 
mice.  The samples were sectioned at 8µm and mounted 
on MAS-coated glass slides (SUPERFROST;  
Matsunami,  Osaka,  Japan).  These were ﬁxed with 4  
paraformaldehyde,  washed with PBS,  incubated with 
10  bovine serum albumin in PBS for 15min,  and 
then incubated with a 1:100 dilution of rabbit FITC-
conjugated anti-active caspase-3 polyclonal antibody 
(BD Biosciences,  Tokyo,  Japan) overnight at 4℃ in 
the dark.  Cell nuclei were counterstained with 
4ʼ, 6-diamidio-2-phenylindole (DAPI) (Roche Applied 
Sciences GmbH,  Mannheim,  Germany) for 2 h in the 
dark.  After washing with PBS,  the samples were 
incubated with a 1 :100 dilution of rabbit 
PE-conjugated anti-CD31 polyclonal antibody (BD 
Biosciences) overnight at 4℃ in the dark and then 
examined by ﬂuorescence microscopy (LSM510; Carl 
Zeiss,  Thornwood,  NY,  USA).
　 Reverse transcription (RT)-polymerase chain 
reaction (PCR) analysis. Samples were extracted 
from whole lung tissues.  RNA samples were prepared 
for RT-PCR using the RNeasy mini kit (Qiagen,  
Germantown,  MD,  USA) according to the manufac-
turerʼs protocol.  The cDNA was synthesized using 
SuperScript II reverse transcriptase (Invitrogen,  
Carlsbad,  CA,  USA).  To speciﬁcally amplify the 
mutant version of mouse Egfr,  the primer EGFR F8del 
(5ʼ-CCTATTCATGCGAAGACGT-3)ʼ,  which spanned 
the deleted portion of the Egfr cDNA,  was designed 
and used with EGFR R5 (5ʼ-AAAGTTGGAGAG 
TCTGTAGGGCT-3ʼ).  Gapdh served as the control 
gene and was ampliﬁed using the primers GAPDH F 
(5ʼ-CGTAGACAAAATGGTGAAGG-3ʼ) and GAPDH 
R (5ʼ-GTTGTCATGGATGACCTTGG-3ʼ).
　 Quantitative PCR. DNA was extracted from 
whole lung tissues using a QIAamp DNA mini kit 
(Qiagen).  The relative level of Egfr expression level,  
as well as the Egfr copy number,  and the cMet copy 
number were analyzed using Duplex TaqMan real-time 
PCR together with an ABI PRISM 5700 Sequence 
Detection System (Applied Biosystems,  Foster City,  
CA,  USA).  The Egfr primers were 5ʼ-CTGCCAAAA 
GTTCCAAGATGAGG-3ʼ and 5ʼ-GGGGCACTTCT 
TCACACAGG-3ʼ; those for cMet were 5ʼ-TTCCCT 
GTATCCACCTATCAAAGTC-3ʼ and 5ʼ-GGACAC 
AGTATTTGCTATGAAGTCG-3ʼ.  Both probes 
(5 ʼ-AGACACCTGCCCACCACTCATGCT-3 ʼ 
and 5ʼ-ACAGACAGACTGCTATGCCTGCCCCT-3,ʼ  
respectively) were labeled with the reporter dye 
6-carboxyﬂuorescein (FAM).  Gapdh was co-ampliﬁed 
in the same reaction mixture as an endogenous refer-
ence gene using TaqMan GAPDH control reagents 
(Sigma-Aldrich,  Tokyo,  Japan).  The average expres-
sion level and copy number of Egfr were determined 
from diﬀerences in the threshold ampliﬁcation cycles 
between Egfr and Gapdh.  A similar method was used 
to determine the copy number of cMet.
　 Sequencing of Egfr. To sequence Egfr,  DNA 
was extracted from whole lung tissues using a QIAamp 
DNA mini kit (Qiagen),  and the exons encoding the 
intracellular domain (exons 18-22) were ampliﬁed by 
PCR.  Primer sequences and ampliﬁcation conditions 
were as described previously [20].  PCR products 
were processed with a Big Dye terminator cycle 
sequencing kit (Biosystems) and analyzed for the pres-
ence of mutations in the sense and antisense directions 
on an ABI 3100 sequencer (Biosystems).
　 Immunoblotting. Protein extracts were pre-
pared from crushed whole lung tissues that had been 
incubated in lysis buﬀer (1  Triton X-100,  0.1  
SDS,  50mM Tris-HCl,  pH7.4,  150mM NaCl,  1mM 
EDTA,  1mM EGTA,  10mM β-glycerol phosphate,  
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10mM NaF,  and 1mM Na-orthovanadate) containing 
protease inhibitors (Roche Diagnostics,  Basel,  
Switzerland).  The extracts were centrifuged at 
14,500 rpm for 20min at 4℃,  and the amount of 
protein was determined by a Bio-Rad protein assay 
(Bio-Rad,  Hercules,  CA,  USA).  Approximately 
50 µg of protein per sample was separated by SDS-
PAGE using 5-15  precast gels (Bio-Rad).  The sepa-
rated proteins were transferred onto nitrocellulose 
membranes,  and speciﬁc proteins were detected by 
enhanced chemiluminescence (GE Healthcare,  
Buckinghamshire,  UK) using the following antibodies:  
phospho-EGFR Y1068,  total EGFR,  total VEGFR-2,  
phospho-Akt Ser473,  total Akt,  phospho-44/42 MAP 
kinase,  total MAP kinase,  phospho-Stat3 (Tyr705),  
total Stat3,  β-actin,  PTEN,  Bcl-xL,  IRS-1,  phos-
pho-IGF-1Rβ Y1135/1136 Y1150/1151,  total 
IGF-1Rβ (1 : 1000 dilution; Cell Signaling 
Technology),  phospho-VEGFR2 Y1054 (1:1000 
dilution; Biosource International) and BIM (1:200 
dilution; Santa Cruz Biotechnology).  The secondary 
antibodies were anti-rabbit IgG antibodies (HRP-
linked,  No. 7074,  species-speciﬁc whole antibodies;  
GE Healthcare),  each of which was used at a 1:5000 
dilution.
　 Statistical analysis. Survival time was deﬁned 
as the period from birth to death.  Survival curves 
were calculated using the Kaplan‒Meier method.  The 
log-rank test was used to detect diﬀerences in survival.  
Statistical signiﬁcance was deﬁned as p＜0.05.  All 
statistical analyses were carried out using SPSS ver-
sion 10.0 (SPSS Inc.,  Chicago,  IL,  USA).
Results
　 Histology of the lungs of the transgenic mice.
Atypical adenomatous hyperplasia,  diﬀuse bronchio-
loalveolar carcinoma,  and invasive adenocarcinoma of 
the lung were identiﬁed in the transgenic mice at 15 
weeks of age (Fig.  1).  The tumors overexpressed total 
EGFR,  phosphorylated EGFR (pEGFR),  VEGFR2,  
and phosphorylated VEGFR2 (pVEGFR2) (Fig.  2A).  
As shown in Fig.  2,  both pEGFR and pVEGFR-2 
were markedly overexpressed in the lungs of trans-
genic mice,  suggesting that VEGFR-2 signaling con-
tributes to tumor progression and growth in this 
transgenic mouse model.  Ultimately,  the transgenic 
mice died at around 17 weeks of age due to multifocal 
invasive adenocarcinoma of the lung.  Multiple macro-
scopic tumor nodules were observed on the lung sur-
face,  and no tumors were found in any other organs.  
In contrast,  non-transgenic control mice did not 
develop lung tumors and survived for over 1 year.
　 Inhibitory effect of vandetanib on lung ade-
nocarcinoma induced by an activating Egfr 
mutation in vivo. To investigate the antitumor 
activity of vandetanib in tumors harboring the activat-
ing Egfr mutation,  7-week-old transgenic mice were 
administered vandetanib (6mg/kg) or vehicle daily for 
7 days,  after which they were killed.  After adminis-
tering vandetanib for 2 days,  the area occupied by 
tumor cells decreased  compared with the pre-adminis-
tration value (Fig.  1B,  C).  Furthermore,  tumor cell 
disappeared in the seeing length after the administra-
tion of vandetanib for 7 days (Fig.  1D).
　 The expression of total EGFR and total VEGFR2 
in the lungs of the transgenic mice,  as assessed by 
immunohistochemistry,  was slightly suppressed in the 
vandetanib-treated animals compared to the animals 
treated with vehicle alone,  while the pEGFR and 
pVEGFR levels were markedly decreased in the 
transgenic mice treated with vandetanib relative to 
those treated with vehicle (Fig.  2).
　 The eﬀect of vandetanib on apoptosis in the lung 
tumors and blood vessels of the transgenic mice was 
also evaluated.  Immunoﬂuorescence showed increased 
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Fig. 1　 A,  Lung tissue of a transgenic mouse at 15 weeks of age 
showing diffuse and solid patterns of bronchioloalveolar 
carcinoma; B,  Adenocarcinoma of the lung in a transgenic mouse 
at 7 weeks of age,  before vandetanib treatment; C and D,  Lung 
tissue of transgenic mice on days 2 (C) and 7 (D) of vandetanib 
treatment (6mg/kg/day).  Adenocarcinoma of the lung was not 
apparent by day 7 of treatment.  Scale bars: 100µm
activated caspase-3 and decreased microvessel density 
in the lung tumors of vandetanib-treated mice com-
pared to vehicle-treated transgenic mice (Fig.  3A).  
Moreover,  apoptosis was induced by vandetanib not 
only in tumor cells but also in CD31-positive endothe-
lial cells (Fig.  3A).  7-week-old transgenic mice were 
treated with vandetanib for 7 days,  after which they 
were killed and the proteins of the lung tissues were 
extracted.  Total EGFR and VEGFR2 levels in the 
lungs of the transgenic mice were similar in the vande-
tanib-treated and vehicle-treated groups,  while pEGFR 
and pVEGFR were markedly decreased in the lungs of 
the mice after 7 days of vandetanib treatment (Fig.  
3B).
　 Effect of vandetanib on survival in the trans-
genic mice. Since lung adenocarcinoma in the 
transgenic mice regressed markedly after vandetanib 
treatment,  the eﬀect of vandetanib on survival was 
examined.  Transgenic mice received vandetanib 
(6mg/kg weekly on days 1-5) or vehicle orally 5 days 
per week from 7 weeks of age until death (n＝6 mice 
per group),  (Fig.  4A).  Vandetanib treatment signiﬁ-
cantly prolonged survival (log-rank test,  p＜0.01;  
Fig.  4B); the median survival time of the vandetanib-
treated mice was 28 weeks,  whereas that of the vehi-
cle-treated mice was 17 weeks.  Multiple recurrent 
lung adenocarcinomas were found in the dead trans-
genic mice,  but metastatic tumors were not detected 
in any other organs (data not shown).  The vandetanib-
treated transgenic mice were killed at various time 
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Fig. 2　 Staining for total EGFR,  pEGFR,  total VEGFR2,  
and pVEGFR in lung tissues of transgenic mice at 13 weeks 
of age after 7 days of treatment with vandetanib (6mg/kg/
day) or vehicle.  Scale bars: 100µm
points to assess the dynamics of tumor recurrence.  
Multiple recurrent adenocarcinomas were present in 
these mice at 20 weeks of age (Fig.  4C).
　 Mechanisms of acquired resistance to vande-
tanib. Known mechanisms of acquired resistance 
to EGFR-TKIs include secondary mutation of EGFR 
[21-23],  cMET ampliﬁcation [24],  type 1 insulin-like 
growth factor receptor (IGF-1R) activation [25,  26],  
and PTEN inactivation [27].  Therefore,  to gain 
insight into the mechanisms of vandetanib resistance,  
total and phosphorylated EGFR and VEGFR2 were 
examined in lung tumors from 8-week-old non-trans-
genic mice (wild-type Egfr) and 8-week-old vehicle-
treated transgenic mice,  as well as 8- and 20-week-
old vandetanib-treated transgenic mice (1 week and 13 
weeks of vandetanib treatment,  which was 6mg/kg 
weekly on days 1-5,  respectively; Fig.  5A).  Vandetanib 
treatment was found to inhibit both EGFR and 
VEGFR signaling even after the tumors had acquired 
resistance to vandetanib (Fig.  5A).  Moreover,  neither 
total EGFR nor VEGFR2 was overexpressed in the 
vandetanib-treated 20-week-old transgenic mice (Fig.  
5A).  Previous studies have shown that the secondary 
EGFR mutation T790M is the major cause of acquired 
resistance to geﬁtinib and erlotinib in vivo and in vitro 
[21-23].  Here,  examination of the transgenic mouse 
tumors for genetic alterations,  including T790M,  
based on sequencing assays of Egfr at exons 18-22 did 
not reveal the mutation within exon 20.  Recently,  
D761Y or L747S mutations at exon 19 were shown to 
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Fig. 3　 A,  Immunoﬂuorescence staining of the lung 
tissues of 13-week-old transgenic mice after 7 days of 
vandetanib (6 mg/kg/day) or vehicle treatment.  Active 
caspase-3 was in the cytoplasm (green),  CD31 (red),  and 
nuclei (DAPI; blue) was visualized by ﬂuorescence 
microscopy.  Active caspase-3 was increased and CD31 
decreased in 13-week-old transgenic mice treated with 
vandetanib for 7 days compared to mice of the same age 
treated with vehicle.  The co-localization of CD31 and 
active caspase-3 is seen on a merged image.  High mag-
niﬁcation was used in the merged portion of vandetanib 
treatment.  Scale bars: 100µm; B,  Total EGFR,  pEGFR,  
total VEGFR2,  and pVEGFR2 levels in the lungs of an 
8-week-old non-transgenic mouse (wild-type EGFR) and in 
a transgenic mouse with adenocarcinoma of the lung.  The 
mice were killed at 8 weeks of age,  after being treated for 
1 week with vandetanib (6 mg/kg/day) or vehicle.  pEGFR 
and pVEGFR in total lysates were detected using a spe-
ciﬁc antibody against pEGFR Y1068 and pVEGFR2 Y1054,  
respectively.
be responsible for acquired EGFR-TKI resistance 
[22,  23]; however,  neither of these mutations was 
detected.  Moreover,  a comparison between the lungs 
of 8-week-old vehicle-treated animals and those of 
20-week-old vandetanib-treated animals failed to reveal 
evidence of a cMet gene ampliﬁcation (using a quantita-
tive PCR method) during treatment with vandetanib 
(Fig.  5B) or altered PTEN protein expression (Fig.  
5A).
　 Phosphorylated Akt (pAkt) levels were reduced in 
8- and 20-week-old vandetanib-treated mice,  whereas 
pSTAT3 levels were similar.  In contrast,  pMAPK 
levels were higher in 8-week-old vehicle-treated trans-
genic mice and 20-week-old vandetanib-treated trans-
genic mice than in 8-week-old vandetanib-treated 
transgenic mice (Fig.  5A).  Note that pIGF-1R was 
overexpressed,  although total IGF-1R remained 
unchanged (Fig.  5A).  Thus,  the mechanisms of 
acquired resistance to vandetanib in the transgenic 
mice may be associated with reestablished signaling 
via the insulin receptor substrate-1 (IRS-1) to the Ras 
kinase signaling cascade.
　 Vandetanib induced apoptosis in the lung tumors of 
the transgenic mice (Fig.  3A).  In previous studies,  
the EGFR-ERK signaling cascade was shown to be 
associated with the pro-apoptotic BH3-only protein 
BIM in apoptosis [28-31],  and BIM has been reported 
to mediate EGFR-TKI-induced apoptosis in lung 
tumors harboring activating EGFR mutations [28,  30,  
31].  We therefore examined the expression levels of 
BIM and anti-apoptotic protein Bcl-xL (basal cell 
lymphoma-extra large) in 8-week-old non-transgenic 
mice,  8-week-old transgenic mice treated with vehicle 
or vandetanib for 1 week,  and 20-week-old transgenic 
mice treated with vandetanib for 13 weeks.  BIM 
expression was elevated in the lungs of both vehicle-
treated and vandetanib-treated transgenic animals 
compared to non-transgenic animals.  However,  BIM 
expression was markedly lower in the 20-week-old 
vandetanib-treated transgenic mice,  while Bcl-xL 
expression was similar in all treatment groups (Fig.  
6).  These data suggest that the suppression of BIM 
expression is one of the mechanisms associated with 
vandetanib resistance.
Discussion
　 Vandetanib,  a tyrosine kinase inhibitor of VEGFR,  
EGFR,  and RET signaling,  suppressed lung adeno-
carcinoma in transgenic mice carrying the activating 
in-frame del Egfr E748-A752 mutation.  Administration 
of the drug inhibited both EGFR signaling and neovas-
cularization and signiﬁcantly prolonged the survival of 
these animals.  However,  the lung adenocarcinomas of 
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Fig. 4　 A,  Vandetanib or vehicle was orally adminis-
tered to transgenic mice 5 days per week until death; B,  
Solid and dotted lines are the survival curves of the 
transgenic mice treated with vandetanib and vehicle,  
respectively; C,  Lung tumors emerged again at 20 weeks 
of age.  Scale bars: 100µm
the transgenic mice eventually acquired resistance to 
vandetanib although none of the well-known mecha-
nisms of resistance—for example,  those involving 
EGFR-TKI,  T790M,  cMet ampliﬁcation or PTEN loss
—were detected.
　 Preclinical studies have demonstrated the eﬃcacy 
of vandetanib in the treatment of lung adenocarcinoma,  
based on the results of orthotopic and subcutaneous 
xenograft experiments [32-34].  Tumors in the lungs 
of our transgenic mice occurred in a more physiologi-
cally relevant setting than is the case for xenograft 
tumors.  In the transgenic mice,  vandetanib inhibited 
tumor growth by blocking EGFR and VEGFR-2 sig-
naling and signiﬁcantly prolonged survival.  These data 
suggest that vandetanib has therapeutic potential for 
patients with lung cancer whose tumors harbor an 
activating EGFR mutation,  and clinical trials with 
vandetanib are under way.  Phase I/II clinical studies 
with vandetanib established the eﬃcacy of a once-daily 
oral dose of up to 300mg [17,  18].  The dose of 
vandetanib administered in the present study (6mg/kg) 
was selected to achieve clinical relevance,  since it 
yielded plasma levels of the drug that were within the 
range of those achieved in a group of Japanese patients 
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Fig. 5　 A,  Total EGFR,  pEGFR,  total VEGFR2,  
pVEGFR2,  total Akt,  pAkt,  total MAP kinase,  pMAP kinase,  
total STAT3,  pSTAT3,  PTEN,  pIGF1R,  and total IGF1R 
levels in the lungs of mice with wild-type Egfr,  8-week-old 
transgenic mice treated with vehicle or vandetanib for 1 week,  
and 20-week-old transgenic mice treated with vandetanib for 
14 weeks; B,  The cMet copy number in the lungs of the 
transgenic mice was determined.  Genomic DNAs extracted 
from the lungs of 8-week-old mice treated with vehicle for 1 
week and 20-week-old transgenic mice treated with vande-
tanib for 14 weeks were compared using TaqMan real-time 
PCR.
with NSCLC administered 100-300mg vandetanib/
day [17,  35].
　 Among the known mechanisms of acquired resis-
tance to EGFR-TKIs,  one of the most important is a 
secondary mutation,  T790M,  in the EGFR ATP-
binding site.  In an ex vivo experiment [34],  vandetanib 
was shown to select or induce the T790M mutation,  
but in our transgenic mouse model,  the mutation could 
not be detected.  Moreover,  vandetanib reduced 
pEGFR in vandetanib-resistant tumor cells in the 
lungs.  Thus,  vandetanib resistance likely arises from 
events downstream of EGFR signaling or through the 
actions of another,  unregulated growth factor recep-
tor,  not through low level competition from a vande-
tanib-ATP-binding site of EGFR other than T790M.  
MET ampliﬁcation and PTEN inactivation were not 
detected,  but pIGF-1R,  IRS,  and pMAPK were 
overexpressed.  IGF-1R stimulates cell proliferation 
and survival by activating the extracellular signal-
regulated kinase (ERK)/mitogen-activated protein 
kinase (MAPK) and Akt pathways [36-40].  IGF-1R 
activation may be associated with pMAPK activation 
and thus involved in vandetanib resistance.  However,  
this remains to be evaluated in further experiments 
investigating the role of IGF-1R inhibition in trans-
genic mice with acquired resistance to vandetanib.
　 Recent studies have revealed that the pro-apoptotic 
BH3-only protein BIM mediated EGFR-TKI-induced 
apoptosis in lung cancers with oncogenic EGFR muta-
tions [28,  30,  31].  BIM is essential for tumor cell 
killing,  and the shutdown of the EGFR-ERK signaling 
cascade is critical for BIM activation.  In our mouse 
model,  BIM was elevated in 8-week-old vandetanib-
treated mice compared to mice of the same age treated 
with vehicle.  BIM may mediate vandetanib-induced 
apoptosis in lung adenocarcinomas,  a conclusion sup-
ported by the fact that the expression of this protein 
was suppressed in vandetanib-resistant mice.  Therefore,  
one of the mechanisms of vandetanib resistance may be 
anti-apoptosis,  in association with the ERK signaling 
cascade and suppression of BIM.
　 In summary,  dual blockade of the EGFR and 
VEGFR signaling pathways by the small molecule 
inhibitor vandetanib has signiﬁcant eﬀects on lung 
adenocarcinomas induced by exon 19 del EGFR (dele-
tion mutation E748-A752).
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